Ceftriaxone Versus Cefazolin Susceptibility as a Surrogate Marker for Cefpodoxime Susceptibility in Enterobacterales

Kaitlyn V Lambert; Ryan Demkowicz; Amanda Murray; Catessa Howard; Douglas Slain

doi:10.1093/ofid/ofae377

Ceftriaxone Versus Cefazolin Susceptibility as a Surrogate Marker for Cefpodoxime Susceptibility in Enterobacterales

Open Forum Infect Dis. 2024 Jul 3;11(7):ofae377. doi: 10.1093/ofid/ofae377. eCollection 2024 Jul.

Authors

Kaitlyn V Lambert¹, Ryan Demkowicz², Amanda Murray², Catessa Howard¹, Douglas Slain^{3

4}

Affiliations

¹ Department of Pharmacy Services, WVU Medicine, Morgantown, West Virginia, USA.
² Department of Microbiology, WVU Medicine, Morgantown, West Virginia, USA.
³ Department of Clinical Pharmacy, Department of Medicine, West Virginia University, Morgantown, West Virginia, USA.
⁴ Section of Infectious Diseases, Department of Medicine, West Virginia University, Morgantown, West Virginia, USA.

Abstract

The Clinical and Laboratory Standards Institute stated that cefpodoxime susceptibility among Enterobacterales can be inferred from cefazolin, but this may overcall cefpodoxime resistance. We report a categorical agreement rate of 64% for cefazolin and 97% for ceftriaxone with cefpodoxime (P = .0001). Ceftriaxone appears to be a more useful cefpodoxime surrogate.

Keywords: Enterobacterales; antimicrobial stewardship; cefazolin; cefpodoxime; ceftriaxone.

Published by Oxford University Press on behalf of Infectious Diseases Society of America 2024.

Publication types

Clinical Trial